Read the article
Read the article
Pharmacopoeia: A New Oxygen Monograph
New Oxygen Monograph Added to the International Pharmacopoeia
The COVID-19 pandemic highlighted severe medical oxygen shortages across many low- and middle-income countries (LMICs). In response, the World Health Organization (WHO) recognized the urgent need to increase the number of Oxygen Generating Plants (OGPs), such as PCI’s Deployable Oxygen Concentration Systems (DOCS). This push led to an update of the International Pharmacopoeia (Ph. Int.), which now includes a new O93% oxygen monograph.
Currently, discussions are underway to determine whether mixing O93% and O99% oxygen concentrations will be allowed. WHO will present the final draft at the 56th meeting of the Expert Committee on Specifications for Pharmaceutical Preparations. The date of this meeting has not yet been set.
About the International Pharmacopoeia
The International Pharmacopoeia (Ph. Int.), published by WHO, provides specifications and test methods for priority medicines with major public health impact. These guidelines play a critical role in ensuring the quality, safety, and effectiveness of pharmaceuticals.
WHO develops the Ph. Int. in collaboration with its Expert Advisory Panel, the Expert Committee on Specifications for Pharmaceutical Preparations, and other global specialists.
VSA Technology
To produce oxygen from air, PCI uses a proprietary Vacuum Swing Adsorption (VSA) process that eliminates many of the design problems associated with traditional on-site gas separation systems (PSA). Our innovative VSA system eliminates the need for process valves, feed air compressors, associated dryers and feed air filtering systems. Our robust VSA oxygen process extracts maximum sieve and power efficiencies = low cost (both CapX and OpX) high purity oxygen generation. Oxygen produced is 93% purity. Additional product/systems features include load following, remote monitoring and diagnostics along with an industry only 10-year warranty on the adsorber bed vessel. Average life span of our systems is 10-15+ years.
About PCI Gases
PCI Gases, headquartered in Riverside, California, is a global leader in advanced on-site gas generation systems. Specializing in Vacuum Swing Adsorption (VSA) technology for oxygen production, the company has been delivering innovative gas separation solutions since 1984. PCI Gases serves a wide range of industries, including medical, industrial, aquaculture, biogas, water treatment, and military applications.With a mission to empower industries by providing autonomy in oxygen and nitrogen supply, PCI Gases helps clients reduce costs and improve sustainability. Their vision is to decentralize gas supply, offering economical and environmentally responsible solutions worldwide. Through a commitment to innovation and operational efficiency, PCI Gases continues to reshape industries and enhance the total cost of ownership for their customers.
Reshape Your Tomorrow!
Posted January 13, 2022
